Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes

Journal of Cystic Fibrosis

Volumn 14, Issue 3, 2015, Pages 370-375

  Dasenbrook, Elliott C ^a,b   Konstan, Michael W ^a,b   VanDevanter, Donald R ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Cystic fibrosis; Inhaled antibiotics; Observational research; Patient registry; Pseudomonas aeruginosa

Indexed keywords

AZTREONAM; COLISTIMETHATE; TOBRAMYCIN; AEROSOL; ANTIINFECTIVE AGENT; COLISTIN; COLISTINMETHANESULFONIC ACID;

ADOLESCENT; ADULT; ARTICLE; CHILD; CYSTIC FIBROSIS; DRUG USE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DISEASE; MALE; PREVALENCE; PSEUDOMONAS AERUGINOSA; AEROSOL; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; FOLLOW UP; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTICENTER STUDY; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AEROSOLS; ANTI-BACTERIAL AGENTS; AZTREONAM; CHILD; COLISTIN; CYSTIC FIBROSIS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; TOBRAMYCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937517616     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.11.005     Document Type: Article

References (12)

1. Doring G., Flume P., Heijerman H., Elborn J.S. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012, 11:461-479.
2. Mogayzel P.J., Naureckas E.T., Robinson K.A., Mueller G., Hadjiliadis D., Hoag J.B., et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013, 187:680-689.
3. Cystic Fibrosis Foundation Patient Registry 2009 annual data report to the center directors 2010, Cystic Fibrosis Foundation, Bethesda, Maryland.
4. Cystic Fibrosis Foundation Patient Registry 2012 annual data report to the center directors 2013, Cystic Fibrosis Foundation, Bethesda, Maryland.
5. VanDevanter D.R., Dasenbrook E.C., Konstan M.W. Incorporation of a third inhaled antipseudomonal antibiotic class into the management of patients at an adult CF care center. J Cyst Fibros 2014, 13:S16.
6. Wang X., Dockery D.W., Wypij D., Fay M.E., Ferris B.G. Pulmonary function between 6 and 18years of age. Pediatr Pulmonol 1993, 15:75-88.
7. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999, 159:179-187.
8. Micallef L., Rodgers P. eulerAPE: Drawing area-proportional 3-Venn diagrams using ellipses. PLoS ONE 2014, 9(7):e101717.
9. VanDevanter D.R., Ballmann M., Flume P.A. Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. Respir Med 2011, 105(Suppl. 2):S18-S23.
10. Moskowitz S.M., Silva S.J., Mayer-Hamblett N., Pasta D.J., Mink D.R., Mabie J.A., et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol 2008, 43:874-881.
11. Bresnik M. Phase 3 study of aztreonam for inhalation solution (AZLI) in a continuous alternating therapy regimen for the treatment of chronic Pseudomonas aeruginosa infection in patients with CF (AZLI CAT). Clinicaltrials.Gov [internet]. Bethesda (md): National library of medicine (us) 2012, [cited 2014 aug 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT01641822 nlm identifier: NCT01641822.
12. VanDevanter D.R., Konstan M.W. Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. Clin Investig 2012, 2(2):163-175.